We still prefer Eli Lilly, even though Viking jumped 25% on early weight loss pill data

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. Viking jumped 25% on early weight loss pill data. We still prefer Eli Lilly. We still like Eli Lilly, but we're not sure if it's the best medicine.

Viking Therapeutics stock jumps more than 15% on promising weight loss pill data. Viking's potential in the budding weight loss market adds to the growing excitement around the biotech company and its potential in weight loss. Viking shares jumped over 15% in the latest trading session.

Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data. Viking Therapeutics emerges as a strong weight loss drug player — or takeover target. Some analysts said the drug may be best in-class.